Please ensure Javascript is enabled for purposes of website accessibility

Medivation Inc. Stock Is Rising Today -- Here's Why

By Brian Feroldi - Feb 26, 2016 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An earnings beat, mixed with upbeat guidance, puts the company's investors in a good mood.

Image source: stevepb via Pixabay.

What: Shares of Medivation (MDVN) were up more than 10% as of 3:00 p.m. ET after the cancer-focused biopharmaceutical company reported its fourth-quarter earnings.

So what: Sales of its cancer medication Xtandi continue to grow strongly. Medivation's collaboration partner Astellas Pharma (ALPMY -1.21%) reported $315.9 million in U.S. sales of Xtandi, up 37% versus the same time last year. Growth outside the U.S. was even stronger and came in at $231 million, up 83%.

Remember that Medivation records Xtandi revenue in three different ways: U.S. collaboration revenue, ex-U.S. collaboration revenue, and up-front and milestone payments.

Here's how those results came in for the quarter:

 Q4 2015Q4 2014Change %
U.S. Collaboration: $157.9 million  $115.1 million 37%
Ex-U.S. Collaboration $44.8 million $18.2 million 146%
Milestone Payments $175 million $141 million 24%

In total, GAAP collaboration revenue for the period came in at $377 million, up 35% from the year-ago period and was ahead of the $371.9 million that analysts were expecting. However, moving forward, it said that it will not be earning more milestone payments from Astellas -- the $175 million it recorded during the period would be its last.

Stripping out the milestone payments revenue came in at $202.7 million, up strongly from the $133.4 million that it reported in the year-ago period. That allowed Medivation to report non-GAAP net income of $49.5 million or $0.29 per diluted share, which was $0.05 higher than analysts were expecting.

The company also confirmed that its supplemental new drug application to expand the labelling of Xtandi has been accepted by the Food and Drug Administration. The agency gave the companies a PDUFA date of Oct. 22, 2016.

The beat on revenue and earnings per share appear to be the reasons that shares are soaring today.

Now what: To keep sales of Xtandi going strong in 2016 the company announced that it increased its specialty sales force more than 40% during the quarter. The company believes that will allow it to more effectively target the roughly 80% of prostate cancer drug prescribing urologists that have yet to write a prescription for Xtandi.

In total, Medivation offered up the following guidance for 2016:

For reference, the company reported non-GAAP collaboration revenue of $695 million in 2015 and non-GAAP earnings per share of $1.01, so the midpoint of its ranges represents growth of roughly 35%. That's roughly in line with what the market was expecting, as analysts were projecting revenue of $910 million and $1.35 in earnings.

Given the solid quarterly numbers and the upbeat forecast, it's hard to blame the market for feeling bullish about Medivation's stock today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Medivation, Inc. Stock Quote
Medivation, Inc.
Astellas Pharma Inc. Stock Quote
Astellas Pharma Inc.
$15.56 (-1.21%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.